Hims & Hers Health (HIMS) Stock Price, Chart, Company Profile & AI Analysis
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more
Hims & Hers Health (HIMS) Stock Analysis: GLP-1 Pivot's Margin Squeeze
Key Takeaways
- Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs.
- Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.
- Strategic partnerships with Novo Nordisk and Eli Lilly for branded GLP-1 offerings reduce regulatory risks but introduce short-term profitability challenges.
- Analyst consensus holds a "Hold" rating with an average price target around $30–$32, reflecting mixed views on growth versus near-term headwinds.
- Subscriber base reached nearly 2.6 million, up 9% year-over-year, signaling sustained demand in personalized telehealth.
Current Market Snapshot
In recent trading sessions, Hims & Hers Health (HIMS) stock has faced heightened volatility, reflecting investor reactions to earnings results and strategic shifts in its high-growth weight-loss segment. The shares have pulled back sharply from earlier peaks amid concerns over margin compression during the transition from compounded to branded GLP-1 therapies. Despite this, broader subscriber growth and raised full-year revenue expectations underscore resilient demand for the company's telehealth platform, which spans sexual health, dermatology, and mental health. Market sentiment remains balanced, with attention on execution in partnerships and international expansion as key drivers for stabilization in the latest market cycle.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds of sophisticated agents that analyze thousands of tickers across diverse market conditions. These bots employ varied strategies—from pattern recognition and trend-following on short timeframes like 5-60 minutes to longer-term momentum plays—delivering impressive stats such as annualized returns up to 171%, win rates of 68–95%, and profit factors exceeding 4.0 in sectors like semiconductors, aerospace, and energy. Only the most suitable bots, proven to outperform benchmarks with risk-adjusted metrics like 100% profitable trades in select 30-day periods or 83% success rates, earn a spot in this dynamic lineup. Traders can explore these high-conviction options tailored to current volatility. Visit the Trending AI Robots page to review performance details and consider integrating them into your strategy.
Recent Developments Driving HIMS Price Action
Hims & Hers Health (HIMS), a leading telehealth provider, has navigated a turbulent period marked by its aggressive pivot in the weight-loss category, directly influencing recent stock price movements. The most significant catalyst was the Q1 2026 earnings release on May 11, which revealed revenue of $608.1 million—up 4% year-over-year but below the $616.85 million consensus—and a net loss of $92.1 million, compared to prior profitability. Adjusted EBITDA fell to $44 million from $91 million a year earlier. This double miss, attributed to elevated costs from transitioning to branded GLP-1 drugs like Novo Nordisk's Wegovy, triggered a 14% share plunge the following day, erasing recent gains and pushing prices toward the low $20s.
Prior to earnings, shares had rallied on strategic announcements. In early April, renewed partnerships with Novo Nordisk and Eli Lilly enabled access to FDA-approved GLP-1 medications, mitigating risks from prior compounded semaglutide sales amid FDA scrutiny. Analysts viewed this as a long-term win, with Needham raising its price target to $35 citing strong demand for over 100,000 monthly weight-loss subscriptions. J.P. Morgan initiated "Overweight" coverage at $35, highlighting reduced regulatory exposure. These deals fueled a multi-week uptrend, with shares climbing toward $30.
However, competitive pressures emerged, including Amazon's GLP-1 program launch via One Medical, which pressured sentiment and contributed to intra-week dips. The pending $1.15 billion acquisition of Eucalyptus, targeting expansion into Australia, Japan, and Europe, added optimism but also integration costs. Post-earnings, analysts diverged: Needham and Canaccord lifted targets to $35 and $32 on growth potential, while Jefferies cut to $24.50 and BofA to $30, citing guidance risks. Consensus holds at "Hold" with a $31.86 average target.
Subscriber growth to 2.6 million (up 9%) signals core strength, but average revenue per user dipped to $80 from $85, reflecting mix shifts. Raised FY2026 revenue guidance to $2.8–$3.0 billion (from $2.7–$2.9 billion) and Q2 at $680–$700 million offered some offset, yet margin concerns dominated, driving the post-earnings selloff. Overall, price action links directly to this GLP-1 evolution: early partnership hype lifted shares, while execution costs exposed vulnerabilities, tempering enthusiasm amid a 52-week range of $13.74–$70.43.
2026 Outlook and Key Factors to Monitor
As Hims & Hers Health advances through 2026, investors should track the execution of its branded GLP-1 strategy, with partnerships alongside Novo Nordisk and Eli Lilly positioning the company to capture sustained demand in the $100 billion weight-loss market while navigating regulatory shifts from the FDA's peptide reviews. Subscriber retention above 85% and Hers brand revenue potentially exceeding $1 billion highlight personalization trends via AI-driven care in specialties like menopause, testosterone, and diagnostics. International growth via the Eucalyptus acquisition could add material revenue from new markets, supporting raised guidance of $2.8–$3.0 billion.
Risks include prolonged margin pressure from higher branded drug costs, with adjusted EBITDA guided at $275–$350 million (10–12% margin), and competitive intensification from Amazon and traditional pharma. Cost structure optimization, including labs and at-home devices, remains critical for scalability. Long-term, 2030 targets of $6.5 billion revenue and $1.3 billion adjusted EBITDA depend on ecosystem expansion and precision medicine. Balanced monitoring of quarterly subscriber adds, GLP-1 prescription ramps, and regulatory updates will inform the trajectory amid telehealth's evolving landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
HIMS in upward trend: 10-day moving average broke above 50-day moving average on June 01, 2026
The 10-day moving average for HIMS crossed bullishly above the 50-day moving average on June 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 27, 2026. You may want to consider a long position or call options on HIMS as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on May 29, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
HIMS moved above its 50-day moving average on May 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HIMS moved out of overbought territory on June 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HIMS broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.391) is normal, around the industry mean (79.619). P/E Ratio (57.137) is within average values for comparable stocks, (97.708). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (3.591) is also within normal values, averaging (96.435).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric